Prognostic significance of Memorial Sloan-Kettering prognostic score in small-cell lung cancer patients

Biomark Med. 2023 Apr;17(7):391-401. doi: 10.2217/bmm-2023-0105. Epub 2023 Jun 29.

Abstract

Aim: To assess the potential factors with predictive value for survival in small-cell lung cancer (SCLC) patients and to develop a nomogram prediction model. Patients & methods: We retrospectively screened and analyzed patients with pathologically confirmed SCLC from April 2015 to December 2021. Results: A total of 167 patients with SCLC were included. According to the Memorial Sloan-Kettering prognostic score (MPS), patients were divided into three groups: group 0 (n = 65), group 1 (n = 69) and group 2 (n = 33). The multivariate analysis showed that MPS was an independent prognostic factor for progression-free and overall survival in SCLC patients (p < 0.05). The nomogram showed that MPS was the most influential factor for overall survival. Conclusion: MPS is an independent prognostic factor for overall and progression-free survival in SCLC patients and performed better than other indicators used in this study.

Keywords: biomarkers; neutrophil-to-lymphocyte ratio; nomogram predictive model; prognostic factor; small-cell lung cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Lung Neoplasms* / diagnosis
  • Nomograms
  • Prognosis
  • Retrospective Studies
  • Small Cell Lung Carcinoma* / diagnosis